A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes
Sponsor: Eli Lilly and Company
A PHASE2 clinical study on Diabetes Mellitus, Type 2 and Obesity, this trial is actively recruiting participants. The trial is conducted by Eli Lilly and Company and has accumulated 5 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Dec 2025 — Jan 2026 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2025 — Dec 2025 [monthly]
Not Yet Recruiting PHASE2
First recorded
Oct 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .